What are the recommended pharmacologic treatment options and dosing for insomnia in adults?

Pharmacological Treatment of Insomnia in Adults

For chronic insomnia in adults, use benzodiazepine receptor agonists (eszopiclone, zolpidem, zaleplon) or dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) as first-line pharmacotherapy, selecting based on whether the patient has sleep-onset insomnia (difficulty falling asleep) versus sleep-maintenance insomnia (difficulty staying asleep). 1

Treatment Algorithm by Insomnia Subtype

For Sleep-Onset Insomnia (Difficulty Falling Asleep):

• First-line options:
  • Zaleplon 10 mg at bedtime 1
  • Zolpidem 10 mg at bedtime (5 mg in elderly/debilitated) 2, 1
  • Triazolam 0.25 mg at bedtime (0.125 mg in elderly) 1
  • Ramelteon 8 mg at bedtime 1

For Sleep-Maintenance Insomnia (Difficulty Staying Asleep):

• First-line options:
  • Suvorexant 10-20 mg at bedtime 1
  • Doxepin 3-6 mg at bedtime 1
  • Eszopiclone 2-3 mg at bedtime (also treats sleep onset) 1
  • Temazepam 15 mg at bedtime (7.5 mg in elderly) 1

For Combined Sleep-Onset and Sleep-Maintenance Insomnia:

• Preferred agents:
  • Eszopiclone 2-3 mg at bedtime 1
  • Zolpidem 10 mg at bedtime or zolpidem CR 12.5 mg 2, 1
  • Temazepam 15 mg at bedtime 1

Evidence Quality and Strength

The 2017 American Academy of Sleep Medicine guideline provides the most comprehensive evidence-based recommendations 1. All recommendations carry WEAK strength under GRADE methodology, reflecting low-to-moderate quality evidence with small effect sizes, not ineffectiveness 1. This downgrading stems from industry funding bias, limited trial numbers per agent, and data heterogeneity 1.

The evidence shows eszopiclone, zolpidem, and suvorexant improve short-term outcomes with small effect sizes 1, 3. Notably, evidence for benzodiazepines, melatonin agonists, and antidepressants was insufficient or too low-strength in systematic reviews 1.

Medications NOT Recommended

Avoid these agents for insomnia treatment 1:

• Trazodone 50 mg (insufficient efficacy data despite widespread off-label use)
• Tiagabine 4 mg (not effective)
• Diphenhydramine 50 mg (anticholinergic risks, especially in elderly)
• Over-the-counter melatonin 2 mg (insufficient evidence)
• Tryptophan 250 mg
• Valerian/herbal preparations
• Barbiturates and chloral hydrate (safety concerns) 2

Newer Agents: Dual Orexin Receptor Antagonists (DORAs)

DORAs represent a mechanistically distinct class that inhibits wakefulness rather than inducing sedation 4. Available agents include:

• Daridorexant (8-hour half-life, 12-month efficacy data) 4
• Lemborexant 4
• Suvorexant (10-20 mg doses studied) 1

DORAs demonstrate no rebound insomnia, no withdrawal symptoms, and minimal abuse potential, distinguishing them from benzodiazepine receptor agonists 4. The European Insomnia Guideline (2023) supports orexin receptor antagonists for periods up to 3 months or longer 5.

Critical Safety Considerations

Benzodiazepine Receptor Agonists (Z-drugs):

• FDA warning: Associated with complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) 2
• Maximum duration: 28 days for zolpidem/zopiclone per some guidelines 6
• Long-term observational data: Increased risk of dementia, fractures, and major injury 3
• Dose reductions required: Women and elderly patients need lower doses due to altered pharmacokinetics 3

Benzodiazepines:

• Should not be used routinely 7
• Longer-acting benzodiazepines (flurazepam) carry residual daytime drowsiness risk 2
• Short-term use only (≤4 weeks) if prescribed 5

Special Population Dosing:

• Elderly patients: Start with half the standard adult dose for most agents 2, 1
• Hepatic impairment: Dose reductions necessary (e.g., eszopiclone max 2 mg, zaleplon 5 mg) 2

Treatment Duration and Monitoring

Pharmacotherapy should be accompanied by:

• Clear treatment goals and expectations
• Education on safety concerns and side effects
• Discussion of cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment 8, 5
• Regular follow-up every few weeks initially to assess effectiveness and adverse effects 2
• Monitoring for dosage escalation and rebound insomnia 2

Duration considerations:

• Most agents studied for short-term use (4 weeks)
• Eszopiclone has no short-term usage restriction in labeling 2
• Orexin antagonists can be used for 3+ months 5
• Longer-term use may be appropriate in select cases, weighing benefits versus risks 5

Clinical Decision Framework

When selecting an agent, prioritize:

1. Symptom pattern (sleep onset vs. maintenance vs. both)
2. Patient age (elderly require dose adjustments)
3. Comorbid conditions (depression, anxiety, substance use history)
4. Medication half-life (avoid long-acting agents causing next-day impairment)
5. Abuse potential (DORAs preferred in patients with substance use concerns)
6. Prior treatment responses
7. Contraindications and drug interactions 2

Common pitfall: Using sedating antidepressants (trazodone) as first-line therapy despite insufficient evidence and significant adverse effect risks 1. While trazodone is widely prescribed off-label, the AASM explicitly recommends against its use 1.

Key caveat: Low-dose doxepin (3-6 mg) is distinct from higher antidepressant doses and has specific evidence for sleep maintenance, unlike other antidepressants 1.